Clinical Trial Update: A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease [Phase 1, Phase 2]

View source ↗

Summary

First-in-human, open-label, dose-escalation trial assessing the safety and tolerability of the gene therapy TTX-381 for ocular manifestations of Neuronal Ceroid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuronal Ceroid Lipofuscinosis Type

Drugs mentioned

• TTX-381

Snippet

Sponsor: Tern Therapeutics, LLC | Conditions: Neuronal Ceroid Lipofuscinosis Type 2 | Phase 1, Phase 2 | Status: RECRUITING